Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6610 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-05 (pharmabiz.net)
STATE: PUJA BETWEEN SPINRAZA AND LIGONUX -
Nusinersen, the treatment for spinal muscular atrophy, stars in a new public purchase. And for the first time, there are two different options for their acquisition. See tender so far, the only therapeutic option carried the signature of the American Biogen, which was presented with its eminraza treatment. However, in October […]
Read more
2025-02-19 (contractpharma.com)
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome – Contract Pharma
Biogen and Stoke Therapeutics entered a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the U.S., Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.
Read more
2025-01-17 (mmm-online.com)
Rx Rundown: Johnson & Johnson, Eli Lilly, the FDA and more
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2024-10-04 (law.com)
Lawsuit Alleging $23 Million Contract Breach Against Biogen Moves Forward
Acting Manhattan Supreme Court Justice Anar Rathod Patel last week denied a motion to dismiss from defendants Reata and Biogen, finding that fact questions remained.
Read more
2014-11-14 (genengnews.com)
Recipharm Acquires Lusomedicamenta for $140M
Deal consolidates 2 European contract development and manufacturing organizations into one of the continent’s largest CDMOs
Read more
(informa.com)
Biogen
Firm signed licensing and development agreement with Swedish pharmaceutical firm KabiVitrum AB to produce and market human somatomedin C, a naturally occurring protein that stimulates growth tissue. Under the agreement, Biogen will provide strains of the recombinant microorganism and develop
Read more